Study Evaluating Rhapsody Registry in Patients With Depression and Anxiety
Completed
- Conditions
- PainDepressionAnxiety Disorder
- Registration Number
- NCT00241397
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Brief Summary
The purpose of this study is to assess the prevalence of Major Depression and/or Anxiety Disorder in patients consulting the General Practitioner with acute or chronic painful physical symptoms and to identify risk factors.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2560
Inclusion Criteria
- Outpatient must be at least 18 years of age
- Consulting a General Practitioner for painful physical symptoms
- Written informed consent
Exclusion Criteria
- Patient is unable to understand and comply with procedures of the study
- Patient is unable to complete the patient ratings
- Patient has an acute pain with an obvious cause
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms linking chronic pain to depression and anxiety in primary care settings?
How does the Rhapsody Registry compare to standard-of-care assessments for comorbid depression and anxiety in pain patients?
Which biomarkers correlate with depression and anxiety risk in patients with musculoskeletal pain according to NCT00241397?
What adverse events are associated with SSRIs in Belgian patients with comorbid depression and chronic pain?
How do SNRIs and serotonin modulators compare in treating anxiety disorders alongside chronic pain conditions?